{"url":"https://newsforagent.com/news/2026-11-03/transgene-poxstg-eev-sitc-2026","markdown_url":"https://newsforagent.com/news/2026-11-03/transgene-poxstg-eev-sitc-2026.md","title":"Transgene to Present PoxSTG-EEV Data at SITC 2026","headline":"Transgene to Present Preclinical PoxSTG-EEV Data at SITC 2026, Backing Systemic Delivery","description":"Transgene will present preclinical PoxSTG-EEV data at SITC 2026, showing intravenous dosing reduced tumor growth in mice and prolonged survival.","section":"Research & Clinical Trials","published_at":"2026-11-03T17:04:36+00:00","modified_at":"2026-11-03T17:04:36+00:00","author":"News Desk","key_takeaways":["Transgene's PoxSTG-EEV poster at SITC 2026 carries abstract number 1050 and is dated November 7, 2026.","In mouse models, intravenous PoxSTG-EEV significantly reduced tumor growth and prolonged survival.","Katell Bidet-Huang, Chief Scientific Officer ad interim, said the preclinical findings show PoxSTG-EEV may address barriers to systemic delivery and intratumoral spread."],"companies":[{"name":"Transgene","is_primary":true,"profile_url":null,"website":"https://www.transgene.fr"}],"source":{"publisher":"TradingView","title":"Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery","url":"https://www.tradingview.com/news/globenewswire:be52f150b094b:0-transgene-to-present-preclinical-data-on-novel-oncolytic-virus-at-sitc-2026-supporting-its-potential-for-systemic-delivery/"},"other_sources":[{"publisher":"Business & Financial","url":"https://menafn.com/1111847115/Advanced-Cervical-Cancer-Clinical-Trial-Pipeline-Appears-Robust-With-70-Key-Pharma-Companies-Actively-Working-In-The-Therapeutics-Segment-Delveinsight"},{"publisher":"EIN Presswire","url":"https://www.einnews.com/pr_news/952070805/the-sarcoma-oncology-center-announces-promising-clinical-data-for-deltarex-g-gene-therapy-at-esmo-2026-madrid-spain"},{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/bizwire-2026-11-3-akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026"}],"tags":["Research & Clinical Trials","Transgene"],"body_markdown":"Transgene will present preclinical data on PoxSTG-EEV, its novel enveloped chimeric oncolytic virus, in a poster at the Society for Immunotherapy of Cancer 2026 Annual Meeting, the company said in a November 3, 2026 announcement covered by [TradingView](https://www.tradingview.com/news/globenewswire:be52f150b094b:0-transgene-to-present-preclinical-data-on-novel-oncolytic-virus-at-sitc-2026-supporting-its-potential-for-systemic-delivery/). Transgene is a French biotech that designs virus-based immunotherapies for cancer, with clinical-stage programs including the myvac individualized neoantigen vaccine platform and the oncolytic virus BT-001.\n\n## What the PoxSTG-EEV Data Showed\n\nPoxSTG-EEV combines Transgene's PoxSTG chimeric viral vector backbone with an Extracellular Enveloped Virion formulation designed to generate and preserve the EEV form of the virus, according to the company. The formulation serves as the backbone for Transgene's proprietary EEVOLV platform.\n\nIn preclinical studies, PoxSTG-EEV showed enhanced cytotoxic activity across multiple tumor cell lines and intratumoral dissemination compared with conventional oncolytic vaccinia viruses, while maintaining infectivity in the presence of active complement and neutralizing antibodies. In mouse models, intravenous administration significantly reduced tumor growth and prolonged survival.\n\n\"These preclinical findings demonstrate the potential of PoxSTG-EEV to address some of these barriers and highlight the continued innovation from Transgene's viral vector expertise,\" said Katell Bidet-Huang, Chief Scientific Officer ad interim at Transgene.\n\nJohann Foloppe, senior scientist and project leader at Transgene, said PoxSTG-EEV \"serves as the backbone for Transgene's proprietary EEVOLV platform, supporting the development of a new generation of poxvirus-based-clinical candidates.\" The poster, abstract number 1050, is titled \"PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery.\"\n\n## Transgene's Run of Vaccine Results\n\nTransgene and NEC reported sustained 100% three-year disease-free survival in patients treated with the neoantigen vaccine TG4050 in a Phase 1/2 trial for head and neck cancer, [Gurufocus](https://www.financialcontent.com/article/bizwire-2026-11-3-akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026) reported in September 2026. Earlier that month, Transgene licensed ProBioGen's AGE1.CR.pIX duck-embryo cell line to support manufacturing of its personalized cancer vaccine, AInvest reported. In October 2026, Transgene appointed Anne Stehlin as chief quality officer and responsible pharmacist, The Pharma Letter reported.\n\n## Other SITC 2026 Presentations\n\nAkamis Bio will present first-in-human Phase 1 data on NG-348, an oncolytic immunotherapy delivering anti-CD3 scFv and CD80 to activate T cells, at SITC 2026 in Phoenix, the FinancialContent Business Page reported on November 3, 2026. The Sarcoma Oncology Center presented updated DeltaRex-G gene therapy data at ESMO 2026, showing a 50% partial response rate and 90% clinical benefit in 10 evaluable patients, [EIN Presswire](https://www.einnews.com/pr_news/952070805/the-sarcoma-oncology-center-announces-promising-clinical-data-for-deltarex-g-gene-therapy-at-esmo-2026-madrid-spain) reported on October 26, 2026.\n\n## When the Poster Appears\n\nSITC 2026 runs November 4 to 8, 2026, in Phoenix, Arizona. Transgene said the poster will be available on the websites of SITC and [Transgene](https://www.transgene.fr) on November 7, 2026, at 9:00 a.m. ET.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}